← Back to Screener
Galmed Pharmaceuticals Ltd. (GLMD)
Price$0.75
Favorite Metrics
Price vs S&P 500 (26W)-55.54%
Price vs S&P 500 (4W)16.42%
Market Capitalization$4.81M
All Metrics
Book Value / Share (Quarterly)$2.40
P/TBV (Annual)0.09x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-0.96
Price vs S&P 500 (YTD)-3.47%
Net Profit Margin (TTM)-424.24%
EPS (TTM)$-2.40
10-Day Avg Trading Volume18.50M
EPS Excl Extra (TTM)$-2.40
EPS (Annual)$-8.09
ROI (Annual)-46.06%
Net Profit Margin (5Y Avg)-5369.04%
Cash / Share (Quarterly)$1.67
ROA (Last FY)-40.65%
EBITD / Share (TTM)$-2.55
ROE (5Y Avg)-80.13%
Operating Margin (TTM)-439.83%
Cash Flow / Share (Annual)$-0.96
P/B Ratio0.30x
P/B Ratio (Quarterly)0.26x
Net Income / Employee (Annual)$-3
EV / Revenue (TTM)0.36x
Net Interest Coverage (TTM)-93.05x
ROA (TTM)-50.39%
EPS Incl Extra (Annual)$-8.09
Current Ratio (Annual)6.55x
Quick Ratio (Quarterly)6.55x
3-Month Avg Trading Volume2.12M
52-Week Price Return-44.45%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$6.28
P/S Ratio (Annual)2.36x
Asset Turnover (Annual)0.02x
52-Week High$2.68
Operating Margin (5Y Avg)-5585.52%
EPS Excl Extra (Annual)$-8.09
Tangible BV CAGR (5Y)-3.20%
26-Week Price Return-46.80%
Quick Ratio (Annual)6.45x
13-Week Price Return-8.21%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)6.55x
Enterprise Value$0.828
Asset Turnover (TTM)0.04x
Book Value / Share Growth (5Y)-40.10%
Revenue / Employee (Annual)$0
Pretax Margin (Annual)-479.41%
Cash / Share (Annual)$1.67
3-Month Return Std Dev98.55%
Net Income / Employee (TTM)$-3
ROE (Last FY)-46.06%
Net Interest Coverage (Annual)-6.64x
EPS Basic Excl Extra (Annual)$-8.09
Receivables Turnover (TTM)0.00x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-2.40
ROI (TTM)-57.04%
P/S Ratio (TTM)2.08x
Pretax Margin (5Y Avg)-5365.36%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$7.99
Price vs S&P 500 (52W)-79.54%
Year-to-Date Return0.67%
5-Day Price Return-0.58%
EPS Normalized (Annual)$-8.09
ROA (5Y Avg)-66.75%
Net Profit Margin (Annual)-483.33%
Month-to-Date Return54.18%
Cash Flow / Share (TTM)$-6.77
EBITD / Share (Annual)$-8.00
Operating Margin (Annual)-525.49%
ROI (5Y Avg)-80.13%
EPS Basic Excl Extra (TTM)$-2.40
P/TBV (Quarterly)0.12x
P/B Ratio (Annual)0.26x
Pretax Margin (TTM)-420.78%
Book Value / Share (Annual)$2.40
Price vs S&P 500 (13W)-11.08%
Beta0.79x
Revenue / Share (TTM)$0.00
ROE (TTM)-57.04%
52-Week Low$0.41
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
2.17
2.17
2.17
2.17
Industry Peers — Pharmaceuticals(309)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
GLMDGalmed Pharmaceuticals Ltd. | 2.08x | — | — | — | $0.75 |
LLYEli Lilly & Co. | 13.45x | 44.70% | 83.04% | 27.59% | $919.90 |
JNJJohnson & Johnson | 5.82x | 7.87% | 67.95% | 14.90% | $230.69 |
ABBVABBVIE INC. | 5.97x | 8.57% | 71.62% | -2.88% | $203.71 |
MRKMerck & Co., Inc. | 4.51x | 1.31% | 78.55% | 21.23% | $117.10 |
AZNAstraZeneca PLC | 5.39x | 8.63% | 81.31% | 21.88% | $200.69 |
NVSNovartis AG | 4.87x | 8.91% | 75.82% | 15.26% | $150.99 |
NVONovo-Nordisk A/S | 3.74x | 6.43% | 80.98% | 20.66% | $40.46 |
ABTAbbott Laboratories | 3.71x | 6.59% | 56.50% | 8.20% | $96.00 |
PFEPfizer Inc. | 2.50x | -1.64% | 75.81% | -3.51% | $27.52 |
BMYBristol-Myers Squibb Co. | 2.52x | -0.22% | 72.63% | — | $59.13 |
About
Galmed Pharmaceuticals is a biopharmaceutical company developing Aramchol, a novel therapeutic candidate for liver disease. The company previously focused Aramchol on non-alcoholic steatohepatitis (NASH) and primary sclerosing cholangitis (PSC), as well as other fibro-inflammatory conditions. Galmed is now advancing development of Aramchol for oncological applications, representing a strategic expansion of the program's potential therapeutic uses.